免疫檢查點阻斷劑Pembrolizumab和Dostarlimab治療晚期及復發性子宮內膜癌的檢視

Immune checkpoint inhibitors pembrolizumab and dostarlimab in the treatment of advanced and recurrent endometrial cancer

免疫治療為近年來癌症領域的熱門研究項目。2023年，美國的NCCN（National Comprehensive Cancer Network）對於子宮內膜癌的治療指引，已經直接將免疫檢查點阻斷劑（immuno-checkpoint inhibitors，ICIs，如pembrolizumab和dostarlimab）加入到治療指引的內容。其中針對晚期或是復發性的子宮內膜癌，除了原先第一線全身性輔助治療，鉑基化療紫杉醇加上卡鉑（paclitaxel+ carboplatin），已經可以直接加上pembrolizumab或是dostalimab當作第一線的標準治療。至於復發性的子宮內膜癌，pembrolizumab加上標靶治療藥物lenvatinib,也提供可行的治療選擇。

Immunotherapy has become a trending topic in the field of cancer research in recent years. This year (2023), the National Comprehensive Cancer Network (NCCN) in the United States has directly included immune checkpoint inhibitors (such as pembrolizumab and dostarlimab) in the treatment guidelines for advance and recurrent endometrial cancer. For advanced stage or recurrent endometrial cancer, in addition to the initial first-line systemic adjuvant treatment with platinum-based chemotherapy (paclitaxel+carboplatin), pembrolizumab or dostalimab can now be added as standard first-line treatment. As for recurrent endometrial cancer, pembrolizumab combined with the targeted therapy drug lenvatinib also provides as a treatment option.